DK3533447T3 - Flydende bendamustinsammensætninger til anvendelse i fremgangsmåde til behandling af bendamustin-responsive tilstande hos patienter som kræver reducerede volumener til indgivelse - Google Patents
Flydende bendamustinsammensætninger til anvendelse i fremgangsmåde til behandling af bendamustin-responsive tilstande hos patienter som kræver reducerede volumener til indgivelse Download PDFInfo
- Publication number
- DK3533447T3 DK3533447T3 DK19151152.6T DK19151152T DK3533447T3 DK 3533447 T3 DK3533447 T3 DK 3533447T3 DK 19151152 T DK19151152 T DK 19151152T DK 3533447 T3 DK3533447 T3 DK 3533447T3
- Authority
- DK
- Denmark
- Prior art keywords
- bendamustine
- administration
- treatment
- methods
- patients requiring
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261613173P | 2012-03-20 | 2012-03-20 | |
| US201261669889P | 2012-07-10 | 2012-07-10 | |
| US201261678715P | 2012-08-02 | 2012-08-02 | |
| EP13765020.6A EP2827863B1 (en) | 2012-03-20 | 2013-03-15 | Liquid composition for use in a method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3533447T3 true DK3533447T3 (da) | 2023-04-24 |
Family
ID=49212373
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13765020.6T DK2827863T3 (da) | 2012-03-20 | 2013-03-15 | Flydende sammensætning til anvendelse i en fremgangsmåde til behandling af bendamustin-responsive tilstande hos patienter der kræver reducerede volumener til indgivelse |
| DK19151152.6T DK3533447T3 (da) | 2012-03-20 | 2013-03-15 | Flydende bendamustinsammensætninger til anvendelse i fremgangsmåde til behandling af bendamustin-responsive tilstande hos patienter som kræver reducerede volumener til indgivelse |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13765020.6T DK2827863T3 (da) | 2012-03-20 | 2013-03-15 | Flydende sammensætning til anvendelse i en fremgangsmåde til behandling af bendamustin-responsive tilstande hos patienter der kræver reducerede volumener til indgivelse |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US9000021B2 (da) |
| EP (3) | EP2827863B1 (da) |
| JP (6) | JP6224064B2 (da) |
| CN (2) | CN104271135B (da) |
| CA (1) | CA2867343C (da) |
| DK (2) | DK2827863T3 (da) |
| ES (2) | ES2943668T3 (da) |
| FI (1) | FI3533447T3 (da) |
| HK (1) | HK1243346A1 (da) |
| HR (2) | HRP20230276T1 (da) |
| HU (2) | HUE062230T2 (da) |
| LT (1) | LT2827863T (da) |
| PL (2) | PL2827863T3 (da) |
| PT (2) | PT2827863T (da) |
| RS (2) | RS58744B1 (da) |
| SI (2) | SI3533447T1 (da) |
| WO (1) | WO2013142359A1 (da) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2528602T (pt) | 2010-01-28 | 2017-01-12 | Eagle Pharmaceuticals Inc | Formulações de bendamustina |
| DK2827862T3 (da) * | 2012-03-20 | 2024-02-12 | Eagle Pharmaceuticals Inc | Formuleringer af bendamustin |
| CA2867343C (en) | 2012-03-20 | 2020-08-11 | Eagle Pharmaceuticals, Inc. | Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration |
| US20230241218A1 (en) * | 2012-07-10 | 2023-08-03 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
| US10905677B2 (en) | 2016-08-31 | 2021-02-02 | Navinta, Llc | Bendamustine solution formulations |
| US11826466B2 (en) | 2016-08-31 | 2023-11-28 | Navinta, Llc | Bendamustine solution formulations |
| US11730815B2 (en) * | 2018-11-26 | 2023-08-22 | Good Health, Llc | Stable liquid pharmaceutical compositions comprising bendamustine |
| JP7235288B2 (ja) * | 2019-01-07 | 2023-03-08 | コーアイセイ株式会社 | ベンダムスチンの液体製剤 |
| CN110123747A (zh) * | 2019-04-26 | 2019-08-16 | 嘉兴市爵拓科技有限公司 | 苯达莫司汀的制剂 |
| WO2021014957A1 (ja) * | 2019-07-22 | 2021-01-28 | 富士フイルム株式会社 | ベンダムスチン注射液製剤 |
| WO2021161876A1 (ja) * | 2020-02-10 | 2021-08-19 | 富士フイルム株式会社 | ベンダムスチン液剤 |
| US20240148696A1 (en) | 2022-10-25 | 2024-05-09 | Softkemo Pharma Inc. | Lyophilized bendamustine-cyclodextrin composition |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE159289C (da) | 1903-10-08 | 1905-03-16 | ||
| US4071620A (en) | 1977-01-10 | 1978-01-31 | American Home Products Corporation | Stabilization of oxygen sensitive dose forms |
| DD159289A1 (de) | 1981-06-01 | 1983-03-02 | Uwe Olthoff | Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen |
| DE3446873A1 (de) | 1984-12-21 | 1986-07-10 | Merckle Gmbh | Fluessige diclofenac-zubereitungen |
| US5223515A (en) | 1988-08-18 | 1993-06-29 | Takeda Chemical Industries, Ltd. | Injectable solution containing a pyridyl methylsulfinylbenzimidazole |
| WO1995019759A1 (en) | 1994-01-24 | 1995-07-27 | The Procter & Gamble Company | Process for solubilizing difficultly soluble pharmaceutical actives |
| ATE526022T1 (de) | 1998-04-20 | 2011-10-15 | Eisai R&D Man Co Ltd | Stabilisierte zusammenstellungen die benzimidazole enthalten |
| WO2002032427A1 (en) | 2000-10-20 | 2002-04-25 | Galephar M/F | Stable oral formulation containing benzimidazole derivative |
| UA82328C2 (uk) | 2002-07-30 | 2008-04-10 | Уайт | Парентеральна композиція на основі гідроксіестеру рапаміцину (варіанти) та спосіб її приготування |
| US20060035945A1 (en) | 2003-05-30 | 2006-02-16 | Giorgio Attardo | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases |
| SE0401842D0 (sv) * | 2004-07-12 | 2004-07-12 | Dizlin Medical Design Ab | Infusion and injection solution of levodopa |
| MX2007005361A (es) | 2004-11-05 | 2008-01-11 | Cephalon Inc | Tratamientos para cancer. |
| US8436190B2 (en) | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
| KR20080039954A (ko) * | 2005-08-31 | 2008-05-07 | 오노 야꾸힝 고교 가부시키가이샤 | 점적용 주사제 |
| JPWO2008020584A1 (ja) | 2006-08-14 | 2010-01-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 安定な凍結乾燥製剤 |
| WO2008044029A1 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
| US8414909B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| DE102007003184A1 (de) | 2007-01-22 | 2008-07-24 | Orlowski, Michael, Dr. | Verfahren zur Beladung von strukturierten Oberflächen |
| US20090082416A1 (en) | 2007-09-25 | 2009-03-26 | Protia, Llc | Deuterium-enriched bendamustine |
| AR072777A1 (es) * | 2008-03-26 | 2010-09-22 | Cephalon Inc | Formas solidas de clorhidrato de bendamustina |
| AU2009296734B2 (en) | 2008-09-25 | 2016-02-18 | Cephalon Llc | Liquid formulations of bendamustine |
| KR20110110293A (ko) | 2009-01-15 | 2011-10-06 | 세파론, 인코포레이티드 | 벤다무스틴 유리 염기의 신규 형태 |
| WO2010097700A1 (en) | 2009-02-25 | 2010-09-02 | Supratek Pharma, Inc. | Bendamustine cyclopolysaccharide compositions |
| US20100273730A1 (en) * | 2009-04-27 | 2010-10-28 | Innopharmax, Inc. | Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof |
| WO2010126676A1 (en) | 2009-04-28 | 2010-11-04 | Cephalon, Inc. | Oral formulations of bendamustine |
| CN101584668A (zh) * | 2009-06-19 | 2009-11-25 | 江苏奥赛康药业有限公司 | 盐酸苯达莫司汀冻干粉针剂 |
| WO2010148288A2 (en) | 2009-06-19 | 2010-12-23 | Lyotropic Therapeutics, Inc. | Pharmaceutical formulations with low aqueous levels of free unbound drug |
| US20110015245A1 (en) | 2009-07-20 | 2011-01-20 | Valery Alakhov | Bendamustine amphiphilic cationic compositions |
| US8389558B2 (en) | 2009-07-20 | 2013-03-05 | Supratek Pharma Inc. | Bendamustine amphiphilic anionic compositions |
| US7772274B1 (en) | 2009-10-19 | 2010-08-10 | Scidose, Llc | Docetaxel formulations with lipoic acid |
| PT2528602T (pt) * | 2010-01-28 | 2017-01-12 | Eagle Pharmaceuticals Inc | Formulações de bendamustina |
| WO2011146882A1 (en) * | 2010-05-21 | 2011-11-24 | Intellikine, Inc. | Chemical compounds, compositions and methods for kinase modulation |
| JP2013540104A (ja) | 2010-07-28 | 2013-10-31 | イーグル・ファーマシューティカルズ・インコーポレーテッド | 延長された保存安定性を有するペメトレキセドを含有する医薬組成物 |
| TWI591074B (zh) | 2011-12-05 | 2017-07-11 | Ｘ 染色體有限公司 | ＰＤＧＦ受體β結合多肽 |
| WO2013112762A1 (en) * | 2012-01-24 | 2013-08-01 | Innopharma, Inc. | Bendamustine compositions and methods therefore |
| WO2013123227A1 (en) | 2012-02-14 | 2013-08-22 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
| CA2867343C (en) | 2012-03-20 | 2020-08-11 | Eagle Pharmaceuticals, Inc. | Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration |
| DK2827862T3 (da) | 2012-03-20 | 2024-02-12 | Eagle Pharmaceuticals Inc | Formuleringer af bendamustin |
-
2013
- 2013-03-15 CA CA2867343A patent/CA2867343C/en active Active
- 2013-03-15 RS RS20190433A patent/RS58744B1/sr unknown
- 2013-03-15 JP JP2015501814A patent/JP6224064B2/ja active Active
- 2013-03-15 LT LTEP13765020.6T patent/LT2827863T/lt unknown
- 2013-03-15 WO PCT/US2013/032295 patent/WO2013142359A1/en active Application Filing
- 2013-03-15 HU HUE19151152A patent/HUE062230T2/hu unknown
- 2013-03-15 RS RS20230252A patent/RS64137B1/sr unknown
- 2013-03-15 US US13/838,267 patent/US9000021B2/en active Active
- 2013-03-15 ES ES19151152T patent/ES2943668T3/es active Active
- 2013-03-15 PT PT13765020T patent/PT2827863T/pt unknown
- 2013-03-15 EP EP13765020.6A patent/EP2827863B1/en active Active
- 2013-03-15 SI SI201332039T patent/SI3533447T1/sl unknown
- 2013-03-15 CN CN201380023660.5A patent/CN104271135B/zh not_active Expired - Fee Related
- 2013-03-15 CN CN201710292508.7A patent/CN107157988A/zh active Pending
- 2013-03-15 HR HRP20230276TT patent/HRP20230276T1/hr unknown
- 2013-03-15 SI SI201331394T patent/SI2827863T1/sl unknown
- 2013-03-15 DK DK13765020.6T patent/DK2827863T3/da active
- 2013-03-15 ES ES13765020T patent/ES2718902T3/es active Active
- 2013-03-15 HU HUE13765020 patent/HUE044233T2/hu unknown
- 2013-03-15 PL PL13765020T patent/PL2827863T3/pl unknown
- 2013-03-15 EP EP23161418.1A patent/EP4218756A1/en active Pending
- 2013-03-15 PT PT191511526T patent/PT3533447T/pt unknown
- 2013-03-15 EP EP19151152.6A patent/EP3533447B1/en active Active
- 2013-03-15 PL PL19151152.6T patent/PL3533447T3/pl unknown
- 2013-03-15 DK DK19151152.6T patent/DK3533447T3/da active
-
2014
- 2014-11-26 US US14/554,269 patent/US20150080444A1/en not_active Abandoned
-
2015
- 2015-03-15 FI FIEP19151152.6T patent/FI3533447T3/fi active
- 2015-08-06 US US14/820,291 patent/US9579384B2/en active Active
-
2017
- 2017-10-04 JP JP2017193917A patent/JP6381761B2/ja active Active
-
2018
- 2018-02-28 HK HK18102930.9A patent/HK1243346A1/zh unknown
- 2018-07-31 JP JP2018143022A patent/JP6738376B2/ja active Active
-
2019
- 2019-04-12 HR HRP20190693TT patent/HRP20190693T1/hr unknown
-
2020
- 2020-05-29 JP JP2020093802A patent/JP2020143143A/ja active Pending
-
2021
- 2021-11-17 JP JP2021186829A patent/JP2022028813A/ja active Pending
-
2023
- 2023-12-15 JP JP2023212014A patent/JP2024037915A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3533447T3 (da) | Flydende bendamustinsammensætninger til anvendelse i fremgangsmåde til behandling af bendamustin-responsive tilstande hos patienter som kræver reducerede volumener til indgivelse | |
| DK3632919T3 (da) | Farmaceutiske sammensætninger omfattende imidazothiadiazol- og imidazopyrazinderivater som proteaseaktiverede receptor 4-(par4)- hæmmere til behandling af blodpladeaggregering | |
| DK2773648T3 (da) | Farmaceutiske forbindelser til anvendelse i behandlingen af clostridium difficile-infektion | |
| DK2938740T3 (da) | Kimære fgf19-peptider til anvendelse til behandling af galdesyrelidelser | |
| DK3329909T3 (da) | Fenfluramin til anvendelse i behandling af dravet syndrom | |
| CO6852068A2 (es) | Formulación líquida estable de etanercept | |
| DK2877574T3 (da) | Alpha (1,2)-fucosyltransferaser egnet til anvendelse i fremstillingen af fucosylerede oligosaccharider | |
| DK3329884T3 (da) | Implanterbar indretning til behandling af glaukom | |
| DK3730136T3 (da) | Anvendelse af ferricitrat til behandlingen af patienter med kronisk nyresygdom | |
| BR112014028602A2 (pt) | formulação líquida. | |
| DK2844279T3 (da) | Doseringsprogrammer til behandling af pompes sygdom | |
| DK3050972T3 (da) | Fremgangsmåder til fremstilling af eicosapentaensyre i thraustochytrider | |
| DK3040336T3 (da) | Forbindelser til brug i behandling af TYK2 Kinase-medierede tilstande | |
| FR2987746B1 (fr) | Seringue pour application medicale | |
| DK2869836T3 (da) | Dna-vaccine til anvendelse hos patienter med pankreascancer | |
| DK2891494T3 (da) | Fremgangsmåde til administration af hypnotisserende/beroligende midler | |
| DK2836203T3 (da) | Vesikulær formulering til anvendelse til behandling af smerter eller nedsat mobilitet i et led | |
| DK2914310T3 (da) | Medicinske indretninger med coatings til forbedret ekkogenicitet | |
| DK3456334T3 (da) | Mælkesyrebakterier til anvendelse i forebyggelse af knogletab hos pattedyr | |
| DK3524260T3 (da) | Farmaceutiske sammensætninger til behandling af manglende appetit | |
| BR112016014512A2 (pt) | formulações farmacêuticas líquidas de pemetrexede | |
| EP2902052A4 (en) | MEDICAL LIQUID ADMINISTRATION DEVICE | |
| DK2735305T3 (da) | Stabiliserede flydende farmaceutiske præparater | |
| DK2938350T3 (da) | Medicinsk formulering til behandling af hypercholesterolæmi | |
| DK3473255T3 (da) | Farmaceutisk formulering omfattende ciclesonid |